NLRP3 and Alzheimer disease: Modern pharmacology studies showed that AD, as a major component of YFBP, could reduce the inflammatory response by inhibiting the activation of the TLR4/NF-κB signaling pathway, and it could also slow down pyroptosis by inhibiting the NLRP3/caspase-1 pathway [35, 36].